On February 18, 2021, the American Journal of Health-System Pharmacy published the results of a meta-analysis evaluating the use of infliximab in patients with rheumatoid arthritis (RA). The meta-analysis evaluated patient response rates to treatment with the infliximab reference product REMICADE compared to treatment with infliximab biosimilars. The study’s authors did not identify statistically significant differences in the attainment rate of ACR20, a 20% improvement in American College of Rheumatology core measures, in response to treatment with the infliximab reference product or biosimilars. The meta-analysis concludes that “[i]n the absence of any meaningful differences in safety or efficacy, biosimilar cost may be the deciding factor in choosing a treatment or agent for formulary inclusion.”